# Biotech Daily Digest ‚Äî 2025-11-06

**45 items from 4 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 11 items
- Fierce Biotech: 10 items
- arXiv q-bio: 23 items


## Eli Lilly Press Releases

- **[Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight](https://investor.lilly.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated)**  
  _Thu, 06 Nov 2025 06:45:00 -0500_  
  Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of


## Endpoints News

- **[UPS, Cencora to expand their US operations; Evotec divests biosimilar business to Sandoz](https://endpoints.news/ups-cencora-to-expand-their-us-operations-evotec-divests-biosimilar-business-to-sandoz/)**  
  _Thu, 06 Nov 2025 14:36:04 +0000_  
  Welcome to Endpoints News‚Äô manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 UPS has acquired US-based supply chain management firm Andlauer Healthcare for  ...

- **[J&J‚Äôs Caplyta approved by FDA as add-on treatment for depression](https://endpoints.news/jjs-caplyta-approved-by-fda-as-add-on-treatment-for-depression/)**  
  _Thu, 06 Nov 2025 14:20:11 +0000_  
  Johnson & Johnson‚Äôs Caplyta has won FDA approval as a new adjunctive treatment for patients with major depressive disorder, bolstering the acquisition that gave the large pharma control of the drug.

 The

- **[Low vaccine uptake hampers Moderna earnings, including meager RSV sales](https://endpoints.news/low-vaccine-uptake-hampers-moderna-earnings-including-meager-rsv-sales/)**  
  _Thu, 06 Nov 2025 12:00:52 +0000_  
  Moderna posted $1 billion in third-quarter revenue, down 45% from the same period a year ago, as shrinking vaccine uptake and a continued inability to crack into the RSV market posed major challenges.

 As a ...

- **[AstraZeneca reports record-breaking quarter, says it can 'absorb impact' of US pricing deal](https://endpoints.news/astrazeneca-reports-record-breaking-quarter-says-it-can-absorb-impact-of-us-pricing-deal/)**  
  _Thu, 06 Nov 2025 11:54:41 +0000_  
  AstraZeneca on Thursday reported its best-ever quarterly sales figures, driven largely by its oncology portfolio.

 The drugmaker's sales between July and September totaled $15.2 billion, up 10% year-on-year at constant exchange rates. This beat analyst ...

- **[Lilly's amylin moves to Phase 3 after success in next obesity drug wave](https://endpoints.news/lillys-amylin-moves-to-phase-3-after-success-in-next-obesity-drug-wave/)**  
  _Thu, 06 Nov 2025 11:45:50 +0000_  
  ATLANTA ‚Äî While its rivals in obesity are fighting, Eli Lilly is reporting fresh data.

 On Thursday, the Indianapolis drugmaker said its experimental amylin receptor agonist, called eloralintide, met the bar for ...

- **[China lifts ban on Illumina's DNA sequencers](https://endpoints.news/china-lifts-ban-on-illuminas-dna-sequencers/)**  
  _Thu, 06 Nov 2025 03:19:41 +0000_  
  China will reverse its ban on importing DNA sequencers from Illumina, the company confirmed on Wednesday, potentially marking a renewed business opportunity in a key market.

 The ban, which was put in place in March ...

- **[Delaware judge refuses to block Metsera from ending Pfizer obesity deal](https://endpoints.news/delaware-judge-refuses-to-block-metsera-from-ending-pfizer-obesity-deal/)**  
  _Wed, 05 Nov 2025 21:27:42 +0000_  
  Pfizer's chances of becoming an obesity drug contender just hit a snag in court.

 A Delaware Court of Chancery judge on Wednesday afternoon denied Pfizer's request for a temporary restraining order that would have prevented ...

- **[First Circuit hears arguments over NIH indirect cost cuts](https://endpoints.news/first-circuit-hears-arguments-over-nih-indirect-cost-cuts/)**  
  _Wed, 05 Nov 2025 20:29:34 +0000_  
  The government is back in court to defend its plan to limit spending on overhead research costs for NIH grantees.

 The US Court of Appeals for the First Circuit heard arguments on Wednesday afternoon over ...

- **[Zealand CEO calls on industry to end the ‚Äòweight loss Olympics‚Äô](https://endpoints.news/zealand-ceo-calls-on-industry-to-end-the-weight-loss-olympics/)**  
  _Wed, 05 Nov 2025 16:00:29 +0000_  
  ATLANTA ‚Äî Zealand Pharma CEO Adam Steensberg thinks it‚Äôs time for the biopharma sector to move past the ‚Äúweight loss Olympics,‚Äù in which investors and other industry insiders fixate on the percentage of weight loss ...

- **[Hepta raises $6.7M to take liquid biopsy into liver disease](https://endpoints.news/hepta-raises-6-7m-to-take-liquid-biopsy-into-liver-disease/)**  
  _Wed, 05 Nov 2025 16:00:04 +0000_  
  Former Illumina, Grail and Google employees are adapting the same blood-based DNA technology used in cancer and prenatal screening to diagnose chronic conditions like liver disease.

 Their new company, Hepta Bio, raised $6.7 million in ...

- **[Lilly partners with AI biologics company; Amgen ends gastric cancer study](https://endpoints.news/lilly-partners-with-ai-biologics-company-amgen-ends-gastric-cancer-study/)**  
  _Wed, 05 Nov 2025 15:27:32 +0000_  
  Plus, news about Rigel Pharmaceuticals, Ultragenyx, Neurocrine Biosciences, TransThera, MoonLake Immunotherapeutics, Kelonia Therapeutics, Johnson & Johnson and Harmony Biosciences:

 üñäÔ∏è Eli Lilly signs deal with XtalPi subsidiary: Lilly will get


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/registrar-snaps-cmc-medical-devices-expand-global-compliance-offering" hreflang="en">Registrar snaps up CMC Medical Devices to expand global compliance offering</a>](https://www.fiercebiotech.com/medtech/registrar-snaps-cmc-medical-devices-expand-global-compliance-offering)**  
  _Nov 6, 2025 7:38am_  
  Registrar Corp., a unit of Paine Schwartz Partners, acquired Spanish medical device consulting services provider CMC Medical Devices, expanding the U.S.-based compliance specialist's global reach.

- **[<a href="https://www.fiercebiotech.com/biotech/eli-lilly-links-amylin-agonist-20-weight-loss-sparking-charge-phase-3" hreflang="en">Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3</a>](https://www.fiercebiotech.com/biotech/eli-lilly-links-amylin-agonist-20-weight-loss-sparking-charge-phase-3)**  
  _Nov 6, 2025 7:38am_  
  Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month.

- **[<a href="https://www.fiercebiotech.com/biotech/modernas-norovirus-phase-3-study-heads-north-again-after-struggling-find-cases" hreflang="en">Moderna's phase 3 norovirus study heads north again after struggling to find cases down south</a>](https://www.fiercebiotech.com/biotech/modernas-norovirus-phase-3-study-heads-north-again-after-struggling-find-cases)**  
  _Nov 6, 2025 7:40am_  
  First, the phase 3 trial of Moderna‚Äôs norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere after failing to find enough cases down south.

- **[<a href="https://www.fiercebiotech.com/biotech/inflammation-biotech-evommune-heads-nyse-150m-ipo" hreflang="en">Inflammation biotech Evommune heads to NYSE with $150M IPO</a>](https://www.fiercebiotech.com/biotech/inflammation-biotech-evommune-heads-nyse-150m-ipo)**  
  _Nov 6, 2025 5:45am_  
  Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO that the inflammation biotech will use to fund a pair of clinical-stage candidates.

- **[<a href="https://www.fiercebiotech.com/biotech/dynavax-pays-vaxart-25m-oral-covid-19-vaccine-program" hreflang="en">Dynavax pays Vaxart $30M for oral COVID-19 vaccine program</a>](https://www.fiercebiotech.com/biotech/dynavax-pays-vaxart-25m-oral-covid-19-vaccine-program)**  
  _Nov 6, 2025 5:02am_  
  Dynavax is paying $30 million upfront for global rights to Vaxart‚Äôs investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the program.

- **[<a href="https://www.fiercebiotech.com/medtech/icecures-cryoablation-treatment-may-extend-survival-some-lung-cancer-patients-study-finds" hreflang="en">IceCure's cryoablation treatment may extend survival in some lung cancer patients, study finds</a>](https://www.fiercebiotech.com/medtech/icecures-cryoablation-treatment-may-extend-survival-some-lung-cancer-patients-study-finds)**  
  _Nov 6, 2025 3:56am_  
  Last month, IceCure Medical‚Äôs tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined with radiation may extend survival for patients with an inoperable form of lung cancer.

- **[<a href="https://www.fiercebiotech.com/biotech/astrazeneca-drops-phase-2-stage-mash-drug-over-disappointing-data" hreflang="en">AstraZeneca drops MASH drug over disappointing phase 2 data</a>](https://www.fiercebiotech.com/biotech/astrazeneca-drops-phase-2-stage-mash-drug-over-disappointing-data)**  
  _Nov 6, 2025 5:22am_  
  AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.

- **[<a href="https://www.fiercebiotech.com/biotech/judge-knocks-down-pfizers-efforts-halt-novo-bid-metsera" hreflang="en">Judge knocks down Pfizer's effort to block Novo's rival bid for Metsera</a>](https://www.fiercebiotech.com/biotech/judge-knocks-down-pfizers-efforts-halt-novo-bid-metsera)**  
  _Nov 5, 2025 5:15pm_  
  Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer‚Äôs request to block Novo Nordisk‚Äôs buyout bid for the biotech, Bloomberg reports.

- **[<a href="https://www.fiercebiotech.com/biotech/ftc-tells-novo-its-metsera-offer-may-violate-us-merger-law-current-form" hreflang="en">FTC warns Novo that current Metsera offer structure may violate US merger law</a>](https://www.fiercebiotech.com/biotech/ftc-tells-novo-its-metsera-offer-may-violate-us-merger-law-current-form)**  
  _Nov 5, 2025 4:02pm_  
  In a letter to lawyers for Novo and Metsera, an FTC official wrote that the proposed purchase of Metsera by the Danish pharma "may violate the procedural provisions" of the Hart-Scott-Rodino (HSR) Act.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-expands-xtalpi-collaboration-345m-antibody-development-pact" hreflang="en">Lilly inks $345M antibody development pact with XtalPi subsidiary</a>](https://www.fiercebiotech.com/biotech/lilly-expands-xtalpi-collaboration-345m-antibody-development-pact)**  
  _Nov 4, 2025 2:29pm_  
  Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery shop as much as $345 million.


## arXiv q-bio

- **[NABench: Large-Scale Benchmarks of Nucleotide Foundation Models for Fitness Prediction](https://arxiv.org/abs/2511.02888)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02888v1 Announce Type: new 
Abstract: Nucleotide sequence variation can induce significant shifts in functional fitness. Recent nucleotide foundation models promise to predict such fitness effects directly from sequence, yet heterogeneous datasets and inconsistent preprocessing make it difficult to compare‚Ä¶

- **[A Roadmap for Predictive Human Immunology](https://arxiv.org/abs/2511.03041)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03041v1 Announce Type: new 
Abstract: For over a century, immunology has masterfully discovered and dissected the components of our immune system, yet its collective behavior remains fundamentally unpredictable. In this perspective, we argue that building on the learnings of reductionist biology and systems‚Ä¶

- **[Novel reaction-diffusion PDE model for fingerprint-like pattern emergence via the Schnakenberg mechanism](https://arxiv.org/abs/2511.03096)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03096v1 Announce Type: new 
Abstract: Fingerprint analysis and fingerprint identification have been the most widely used tools for human identification. To this day, various models have been proposed to explain how fingerprints are formed, ranging from the fibroblast model, which focuses on cell-collagen in‚Ä¶

- **[Topography, climate, land cover, and biodiversity: Explaining endemic richness and management implications on a Mediterranean island](https://arxiv.org/abs/2511.03242)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03242v1 Announce Type: new 
Abstract: Island endemism is shaped by complex interactions among environmental, ecological, and evolutionary factors, yet the relative contributions of topography, climate, and land cover remain incompletely quantified. We investigated the drivers of endemic plant richness acros‚Ä¶

- **[FAPEX: Fractional Amplitude-Phase Expressor for Robust Cross-Subject Seizure Prediction](https://arxiv.org/abs/2511.03263)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03263v1 Announce Type: new 
Abstract: Precise, generalizable subject-agnostic seizure prediction (SASP) remains a fundamental challenge due to the intrinsic complexity and significant spectral variability of electrophysiological signals across individuals and recording modalities. We propose FAPEX, a novel‚Ä¶

- **[The Evolution of Life as a Categorical Information-Handling Process](https://arxiv.org/abs/2511.03346)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03346v1 Announce Type: new 
Abstract: Living systems can be understood as organized entities that capture, transform, and reproduce information. Classical gene-centered models explain adaptation through frequency changes driven by differential fitness, yet they often neglect the higher-order organization an‚Ä¶

- **[A Gene Ranking Framework Enhances the Design Efficiency of Genome-Scale Constraint-Based Metabolic Networks](https://arxiv.org/abs/2511.03483)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03483v1 Announce Type: new 
Abstract: The design of genome-scale constraint-based metabolic networks has steadily advanced, with an increasing number of successful cases achieving growth-coupled production, in which the biosynthesis of key metabolites is linked to cell growth. However, a major cause of desi‚Ä¶

- **[Physical fitness post VO2max - a computational framework](https://arxiv.org/abs/2511.03546)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03546v1 Announce Type: new 
Abstract: This paper critically examines the conceptual and methodological limitations underlying the current understanding and application of VO2max in exercise science and physical activity prescription. Despite the establishment of WHO guidelines on physical activity, populati‚Ä¶

- **[Impact of Resistance Development Mechanisms on Antibiotic Treatment Outcomes](https://arxiv.org/abs/2511.03677)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03677v1 Announce Type: new 
Abstract: Bacteria develop resistance to antibiotics through various mechanisms, with the specific mechanism depending on the drug-bacteria pair. It remains unclear, however, which resistance mechanism best supports favorable treatment outcomes, specifically in clearing infection‚Ä¶

- **[Asymptotic analysis of a stochastic SVEIS epidemic model using Black-Karasinski process](https://arxiv.org/abs/2511.02882)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02882v1 Announce Type: cross 
Abstract: In this paper, we present a stochastic SVEIS epidemic model perturbed by a Black-Karasinski process. Using a Lyapunov functional approach, we derive a sufficient condition, Rs0>1 for the existence of a stationary distribution, which indicates disease persistence. Addi‚Ä¶

- **[Scalable Single-Cell Gene Expression Generation with Latent Diffusion Models](https://arxiv.org/abs/2511.02986)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02986v1 Announce Type: cross 
Abstract: Computational modeling of single-cell gene expression is crucial for understanding cellular processes, but generating realistic expression profiles remains a major challenge. This difficulty arises from the count nature of gene expression data and complex latent depen‚Ä¶

- **[FP-AbDiff: Improving Score-based Antibody Design by Capturing Nonequilibrium Dynamics through the Underlying Fokker-Planck Equation](https://arxiv.org/abs/2511.03113)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03113v1 Announce Type: cross 
Abstract: Computational antibody design holds immense promise for therapeutic discovery, yet existing generative models are fundamentally limited by two core challenges: (i) a lack of dynamical consistency, which yields physically implausible structures, and (ii) poor generaliz‚Ä¶

- **[Morpho-Genomic Deep Learning for Ovarian Cancer Subtype and Gene Mutation Prediction from Histopathology](https://arxiv.org/abs/2511.03365)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03365v1 Announce Type: cross 
Abstract: Ovarian cancer remains one of the most lethal gynecological malignancies, largely due to late diagnosis and extensive heterogeneity across subtypes. Current diagnostic methods are limited in their ability to reveal underlying genomic variations essential for precision‚Ä¶

- **[Computational Imaging Meets LLMs: Zero-Shot IDH Mutation Prediction in Brain Gliomas](https://arxiv.org/abs/2511.03376)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03376v1 Announce Type: cross 
Abstract: We present a framework that combines Large Language Models with computational image analytics for non-invasive, zero-shot prediction of IDH mutation status in brain gliomas. For each subject, coregistered multi-parametric MRI scans and multi-class tumor segmentation m‚Ä¶

- **[Final state sensitivity and fractal basin boundaries from coupled Chialvo neurons](https://arxiv.org/abs/2511.03671)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2511.03671v1 Announce Type: cross 
Abstract: We investigate and quantify the basin geometry and extreme final state uncertainty of two identical electrically asymmetrically coupled Chialvo neurons. The system's diverse behaviors are presented, along with the mathematical reasoning behind its chaotic and nonchaot‚Ä¶

- **[Modelling the interaction between ethnicity and infectious disease transmission dynamics in Aotearoa New Zealand during the first Omicron wave of the COVID-19 pandemic](https://arxiv.org/abs/2507.10925)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2507.10925v2 Announce Type: replace 
Abstract: During the COVID-19 pandemic, Aotearoa followed an elimination strategy followed by a mitigation strategy, which saw high success and kept health impact low. However, there were inequities in health outcomes, notably that M\=aori and Pacific Peoples had lower vaccin‚Ä¶

- **[Response function as a quantitative measure of consciousness in brain dynamics](https://arxiv.org/abs/2509.00730)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2509.00730v2 Announce Type: replace 
Abstract: Understanding the neural correlates of consciousness remains a central challenge in neuroscience. In this study, we investigate the relationship between consciousness and neural responsiveness by analyzing intracranial ECoG recordings from non-human primates across‚Ä¶

- **[Personalized Transcranial Electrical Stimulation: A Review of Computational Modeling and Optimization](https://arxiv.org/abs/2509.01192)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2509.01192v2 Announce Type: replace 
Abstract: Objective. Personalized transcranial electrical stimulation (tES) has gained growing attention due to the substantial inter-individual variability in brain anatomy and physiology. While previous reviews have discussed the physiological mechanisms and clinical applic‚Ä¶

- **[Individualizing Glioma Radiotherapy Planning by Optimization of Data and Physics-Informed Discrete Loss](https://arxiv.org/abs/2312.05063)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2312.05063v4 Announce Type: replace-cross 
Abstract: Brain tumor growth is unique to each glioma patient and extends beyond what is visible in imaging scans, infiltrating surrounding brain tissue. Understanding these hidden patient-specific progressions is essential for effective therapies. Current treatment pla‚Ä¶

- **[One pathogen does not an epidemic make: A review of interacting contagions, diseases, beliefs, and stories](https://arxiv.org/abs/2504.15053)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2504.15053v2 Announce Type: replace-cross 
Abstract: From pathogens and computer viruses to genes and memes, contagion models have found widespread utility across the natural and social sciences. Despite their success and breadth of adoption, the approach and structure of these models remain surprisingly siloed‚Ä¶

- **[Optical turbulence retrieval of heterogeneous media](https://arxiv.org/abs/2506.13204)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2506.13204v2 Announce Type: replace-cross 
Abstract: The transport of intensity equation (TIE) has revolutionized phase retrieval in optical microscopy, yet its application to complex media with absorption/scattering remains challenging. Here, we present a coupled TIE-TPE (transport of phase equation) framework‚Ä¶

- **[DiffSpectra: Molecular Structure Elucidation from Spectra using Diffusion Models](https://arxiv.org/abs/2507.06853)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2507.06853v2 Announce Type: replace-cross 
Abstract: Molecular structure elucidation from spectra is a fundamental challenge in molecular science. Conventional approaches rely heavily on expert interpretation and lack scalability, while retrieval-based machine learning approaches remain constrained by limited re‚Ä¶

- **[Fast weight programming and linear transformers: from machine learning to neurobiology](https://arxiv.org/abs/2508.08435)**  
  _Thu, 06 Nov 2025 00:00:00 -0500_  
  arXiv:2508.08435v2 Announce Type: replace-cross 
Abstract: Recent advances in artificial neural networks for machine learning, and language modeling in particular, have established a family of recurrent neural network (RNN) architectures that, unlike conventional RNNs with vector-form hidden states, use two-dimensiona‚Ä¶
